Belgian, Swiss, and US researchers have found a new way to boost efficacy in cancer immunotherapy. In mid-April, they reported that cancer cells actively block tumour infiltration of cytotoxic T cells, but that this process can be reversed using angiogenesis blockers. Some Big pharma companies have already jumped on the bandwagon of angiogenesis/PDL1 combination therapy.
Macrophage Pharma backed by Merck Ventures
Latest NewsMerck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd.
Parkinson’s: factor protects from neuron decay
Latest NewsScientists at Swedish Karolinska Institute have identified a factor that supports growth of midbrain dopaminergic (mDA) neurons, the nerve cells that degenerate during of Parkinson’s disease.
Topas Therapeutics lands option deal with Eli Lilly
Latest NewsEvotec’s immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification of antigens that specifically induce a T regulatory cell response in inflammatory and auto-immune disorders.
New CFO for Pharmalink
AppointmentsSwedish specialty pharmaceutical company Pharmalink AB Stockholm has Fredrik Johansson as new Chief Financial Officer.
Medivir licenses HCV drug MIV-802 to Chinese Ascletis
Latest NewsMedivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd.
Checkpoint modulation: Blocking the tumour’s immune evasion strategies
BackgroundBelgian, Swiss, and US researchers have found a new way to boost efficacy in cancer immunotherapy. In mid-April, they reported that cancer cells actively block tumour infiltration of cytotoxic T cells, but that this process can be reversed using angiogenesis blockers. Some Big pharma companies have already jumped on the bandwagon of angiogenesis/PDL1 combination therapy.
Swedish reasearchers link up cancer survival to protein levels
Latest NewsUsing a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival.
Metsä Group started up its bioproduct mill
Latest NewsFinnish Metsä Group has started its mill for bio-based products. The €1.2bn investment’s production capacity is 1.3 million tonnes of softwood pulp a year.
Oxford Immunotec value drops after public offering
Latest NewsUK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.
Cleaning up the oceans
BackgroundFrench green chemistry pioneer, Carbios SA (Clermont-Ferrand) announced in March that it has secured equity financing of €2.5m from Kepler Cheuvreux through the acquisition of 380,000 shares over 24 months.